mdgroup and Q2 Solutions to Join DTRA Podcast for Discussion on Barriers Between Vendors and Service Providers
As part of the Decentralized Trials and Research Alliance's (DTRA) TGIF-DCT podcast series, mdgroup will join forces with Q2 Solutions to explain how tearing down barriers between the various vendors and service providers involved in such studies is a simple yet effective starting point.
Hosted by DTRA founder Craig Lipset, mdgroup's Director of Decentralized Clinical Solutions, Tom Brazier, will present with Q2 Solutions' Decentralized Trial Solutions Director, John Corcoran, and Manager, Stephanie Larimer.
This event will take place on Dec. 9, 12-1pm, EST. This podcast discussion forms part of a series of Clubhouse events, organized by the DTRA, of which mdgroup is a founding member, aimed at providing all stakeholders with an informal space to share DCT experiences and best practice.
Read more about the event here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
